Targeting EGFR therapeutically using anti-EGFR monoclonal antibodies or kinase domain inhibitors with concomitant radiation remains one therapeutic option for patients with HNSCC [7,9,10]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.